Qlife postpones the publication of the year-end report for the financial year 2023 until 8 February 2024

2024-02-04 21:53

Qlife postpones the publication of the year-end report for the financial year 2023 until 8 February 2024

Qlife Holding AB has decided to postpone the publication of the year-end report for the financial year 2023. The previously announced date for publication was Monday, 5 February 2024. The new date for publication is Thursday, 8 February 2024.

The postponement is due to administrative reasons.

This information was submitted for publication, through the agency of the contact person set out above, on 04-02-2024 21:53 CET.

2024-10-07 20:06

Kallelse till extra bolagsstämma i Qlife Holding AB tillika andra kontrollstämma

2024-10-07 19:59

Qlife withdraws proposal to change company name

2024-10-02 08:55

Qlife starts sales of its PHE rare disease test, addressing an unmet need in the at-home testing market worth SEK 2.5 billion

2024-10-01 09:00

Qlife starts sales of its PHE rare disease test, addressing an unmet need in the at-home testing market worth SEK 2.5 billion

2024-09-10 09:00

Qlife is pleased to announce that Peter Warthoe will return to the management group as Chief Scientific Officer

2024-09-06 13:03

Qlife Holding AB (publ) is pleased to announce that it publishes a second balance sheet for liquidation purposes showing that the Company's total equity exceeds the registered share capital

2024-09-04 09:00

Production of Egoo consumables now established in China to support on-going clinical trials and future sales

2024-08-29 22:44

Qlife provides strategic business update and plans rebranding as 'Egoo Health' – a new era begins

2024-08-29 22:33

Qlife acquires the assets of Qlife ApS, carries out directed issues of a total of approx. MSEK 6.90 and proposal of directed issues of approx. MSEK 5.05